Actemra Access: Roche Open To Partnering Patent Pools
Executive Summary
Roche is open to considering tie-ups with the Medicines Patent Pool or other voluntary patent pools to assess partners for Actemra, as part of efforts to broaden access to the immunotherapy for COVID-19. With a patent non-assert declaration on tocilizumab already in place, activists say the geographic scope of patent licenses will need to be broadened to have any real impact.
You may also be interested in...
Roche Tocilizumab IP Relaxation Does Not Go Far Enough
After the WHO recommended the use of IL-6 receptor blockers to treat patients hospitalized with severe or critical COVID-19, Actemra/RoActemra originator Roche pledged not to enforce IP covering the tocilizumab brand in low- and middle-income countries during the pandemic. But humanitarian organization MSF says this does not go far enough.
Coronavirus Update: Once Written Off, Roche's Actemra Finally Gets EUA In COVID-19
Actemra finally gains an emergency use authorization, Lilly's antibodies withdrawn again amid Delta variant concerns, plus Latin America’s belief in an anti-parasite drug in COVID-19 could soon be punctured.
How Cipla Is Shaping Lung Leadership Beyond Asthma, AMR Plans
CEO Umang Vohra outlines where Cipla is heading in its priority areas of lung route therapies and antimicrobial resistance. He also weighs in on the simmering issue of intellectual property waivers for COVID-19 vaccines.